



# MARKET RELEASE

28 October 2011

**CBio Limited**

**TRADING HALT**

The securities of CBio Limited (the "Company") will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Tuesday, 1 November 2011 or when the announcement is released to the market.

Security Code:           CBZ

Kimberley Brown  
Senior Adviser, Listings (Sydney)

28 October 2011

Senior Adviser, Issuers  
ASX Markets Supervision Pty Ltd  
20 Bridge St  
SYDNEY NSW 2000

BY EMAIL

### Trading Halt Request

I confirm that CBio Limited ("CBio" or "Company") wishes to request a trading halt in its securities and provides the following information in accordance with Listing Rule 17.1:-

- The request for the trading halt is pending the release of an announcement regarding a material capital raising.
- The trading halt is to last until the earlier of the Company releasing an announcement, or the commencement of trade on Tuesday, 1 November 2011.
- It is expected that the trading halt will be ended by the Company making an announcement of the kind referred to above.
- The Company is not aware of any reason why the trading halt should not be granted.

Please contact me if you require any further information concerning this matter.

Yours sincerely



Roslynn Shand  
Company Secretary  
CBio Limited

#### **About CBio Limited**

CBio is an Australian ASX listed company established in 2000. CBio's lead product XToll® is a potential new-generation drug therapy which could provide safer and more effective treatment of autoimmune diseases such as rheumatoid arthritis (RA). Global sales of RA therapies exceeded US\$17 billion in 2008. Novo Nordisk A/S, a top 20 global pharmaceutical company and world-leader in diabetes care, has an exclusive option to enter into a licence agreement for the intellectual property rights relating to XToll®. XToll® has been trialled in over 330 patients with no pattern of treatment-emergent serious adverse effects. The company's largest clinical trial to date completed in Q2 2011. CBio's Board includes internationally experienced drug developers including Dr Goran Ando, Vice-Chairman Novo Nordisk A/S (formerly president of R&D at Pharmacia/Pfizer and R&D director of Glaxo Group, UK); Dr Thomas Lönngren (former Executive Director of the European Medicines Agency), Dr Terje Kalland, Chief Scientific Officer of Karolinska Development (formerly Senior-Vice President Biopharmaceuticals Research Unit- Novo Nordisk and Head of Oncology Research, Pharmacia); Dr Peter Corr, Founder and co-General Partner of Celtic Therapeutics (formerly Senior Vice-President for Science and Technology at Pfizer and Chairman of the Board of Governors, New York Academy of Sciences); and Professor John Funder, AO, Professor of Medicine at Monash University, Senior Fellow at Prince Henry's Institute of Medical Research (formerly Director of the Baker Institute, 1990-2001).

#### **About Rheumatoid Arthritis**

Rheumatoid Arthritis is a chronic autoimmune disease, mainly characterised by inflammation of the lining of the joints. It can lead to long-term joint damage, resulting in chronic pain, loss of function and disability. The effects of RA are systemic, which means it can affect other organs in the body, and cardiovascular dysfunction in addition to RA is common. RA symptoms can make even the simplest activities – such as opening a jar or taking a walk – difficult to manage. RA has a worldwide distribution with a prevalence of 1 to 2% – which currently equates to approximately 100 million people. Prevalence increases with age, approaching 5% in women over age 55. RA is two to three times more common in women than in men and generally occurs between the ages of 40 and 60, but it can also affect young children and older adults. Currently, there is no cure.

#### **ENQUIRIES:**

Melanie Farris  
Manager, Corporate Projects  
CBio Limited  
T: +61 449 148 448  
[melanie.farris@cbio.com.au](mailto:melanie.farris@cbio.com.au)